SI2686002T1 - A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen - Google Patents

A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen Download PDF

Info

Publication number
SI2686002T1
SI2686002T1 SI201231281T SI201231281T SI2686002T1 SI 2686002 T1 SI2686002 T1 SI 2686002T1 SI 201231281 T SI201231281 T SI 201231281T SI 201231281 T SI201231281 T SI 201231281T SI 2686002 T1 SI2686002 T1 SI 2686002T1
Authority
SI
Slovenia
Prior art keywords
interferon
patient
use according
week
needle
Prior art date
Application number
SI201231281T
Other languages
English (en)
Slovenian (sl)
Inventor
Aaron Deykin
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of SI2686002T1 publication Critical patent/SI2686002T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
SI201231281T 2011-03-15 2012-03-15 A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen SI2686002T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161452807P 2011-03-15 2011-03-15
US201161476930P 2011-04-19 2011-04-19
EP12719487.6A EP2686002B1 (en) 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
PCT/US2012/029201 WO2012125809A1 (en) 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Publications (1)

Publication Number Publication Date
SI2686002T1 true SI2686002T1 (en) 2018-06-29

Family

ID=46045072

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231281T SI2686002T1 (en) 2011-03-15 2012-03-15 A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen

Country Status (25)

Country Link
US (6) US9198955B2 (cg-RX-API-DMAC7.html)
EP (1) EP2686002B1 (cg-RX-API-DMAC7.html)
JP (2) JP6279905B2 (cg-RX-API-DMAC7.html)
KR (1) KR102050339B1 (cg-RX-API-DMAC7.html)
CN (1) CN103702680A (cg-RX-API-DMAC7.html)
AU (1) AU2012229104B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013023609A8 (cg-RX-API-DMAC7.html)
CA (1) CA2846786C (cg-RX-API-DMAC7.html)
CY (1) CY1120176T1 (cg-RX-API-DMAC7.html)
DK (1) DK2686002T3 (cg-RX-API-DMAC7.html)
EA (1) EA028448B1 (cg-RX-API-DMAC7.html)
ES (1) ES2666850T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180621T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036931T2 (cg-RX-API-DMAC7.html)
IL (1) IL228425A (cg-RX-API-DMAC7.html)
LT (1) LT2686002T (cg-RX-API-DMAC7.html)
MX (1) MX359947B (cg-RX-API-DMAC7.html)
PL (1) PL2686002T3 (cg-RX-API-DMAC7.html)
PT (1) PT2686002T (cg-RX-API-DMAC7.html)
RS (1) RS57175B1 (cg-RX-API-DMAC7.html)
SG (1) SG193446A1 (cg-RX-API-DMAC7.html)
SI (1) SI2686002T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800221T1 (cg-RX-API-DMAC7.html)
WO (1) WO2012125809A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201306933B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013023609A8 (pt) * 2011-03-15 2018-04-03 Biogen Idec Inc Método para a redução de sintomas parecidos com a gripe associado com a administração intramuscular de interferon ao usar um regime de dosagem escalonado de titulação rápida
HK1226092A1 (zh) 2014-01-09 2017-09-22 Kyushu University, National University Corporation 制备小胶质细胞的方法
WO2018056584A1 (ko) 2016-09-21 2018-03-29 삼성전자 주식회사 피부 상태 측정 방법 및 이를 위한 전자 장치
WO2022069250A1 (en) * 2020-09-30 2022-04-07 Koninklijke Philips N.V. Methods and systems for performing dose titration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
WO1982002715A1 (fr) 1981-02-04 1982-08-19 Sugano Haruo Gene d'interferon (beta)humain
US4695543A (en) 1982-03-23 1987-09-22 Bristol-Myers Company Alpha Interferon GX-1
CA1302320C (en) 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
FI90990C (fi) 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
US4885166A (en) 1985-06-11 1989-12-05 Ciba-Geigy Corporation Hybrid interferons
US5641656A (en) 1993-10-22 1997-06-24 University Of Connecticut Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them
PL193447B1 (pl) * 1996-12-24 2007-02-28 Biogen Idec Inc Kompozycja interferonu, kompozycja farmaceutycznainterferonu oraz sposób stabilizowania kompozycjiinterferonu
JP2001104482A (ja) * 1999-10-07 2001-04-17 Terumo Corp ２室型プレフィルドシリンジ
ES2712469T3 (es) * 2003-01-30 2019-05-13 Becton Dickinson Co Soporte con escudo de seguridad para un dispositivo de administración de fármaco
EA010979B1 (ru) * 2004-06-01 2008-12-30 Арес Трейдинг С.А. Стабилизированные жидкие препаративные формы интерферона
US20060089593A1 (en) * 2004-10-26 2006-04-27 Sergio Landau Needle-free injection device for individual users
EP1923085A1 (en) * 2006-11-17 2008-05-21 Sanofi-Aventis Deutschland GmbH Dosing and drive mechanism for drug delivery device
EP2486916B1 (en) 2006-12-18 2015-04-01 Ajinomoto Althea, Inc. Human growth hormone formulations
US9044378B2 (en) * 2007-05-31 2015-06-02 Safety Syringes, Inc. Anti-needle stick safety device or system for use with drugs requiring reconstitution
JP5549048B2 (ja) * 2007-08-16 2014-07-16 味の素株式会社 薬剤バイアルとプレフィルドシリンジの接続構造
WO2010148337A1 (en) * 2009-06-18 2010-12-23 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
BR112013023609A8 (pt) * 2011-03-15 2018-04-03 Biogen Idec Inc Método para a redução de sintomas parecidos com a gripe associado com a administração intramuscular de interferon ao usar um regime de dosagem escalonado de titulação rápida

Also Published As

Publication number Publication date
HUE036931T2 (hu) 2018-08-28
HRP20180621T1 (hr) 2018-07-27
AU2012229104A1 (en) 2013-10-03
WO2012125809A1 (en) 2012-09-20
EA201301024A1 (ru) 2014-03-31
US20220280610A1 (en) 2022-09-08
JP6279905B2 (ja) 2018-02-14
DK2686002T3 (en) 2018-04-30
BR112013023609A8 (pt) 2018-04-03
CA2846786A1 (en) 2012-09-20
NZ616536A (en) 2015-10-30
PL2686002T3 (pl) 2018-10-31
KR102050339B1 (ko) 2019-11-29
JP6522069B2 (ja) 2019-05-29
US20170360890A1 (en) 2017-12-21
MX2013010507A (es) 2014-04-30
US20120237479A1 (en) 2012-09-20
US20160101157A1 (en) 2016-04-14
PT2686002T (pt) 2018-04-23
CN103702680A (zh) 2014-04-02
CY1120176T1 (el) 2018-12-12
EP2686002A1 (en) 2014-01-22
SG193446A1 (en) 2013-10-30
CA2846786C (en) 2022-05-17
EP2686002B1 (en) 2018-01-24
IL228425A (en) 2017-08-31
LT2686002T (lt) 2018-05-10
ES2666850T3 (es) 2018-05-08
AU2012229104B2 (en) 2017-03-16
BR112013023609A2 (pt) 2016-12-06
RS57175B1 (sr) 2018-07-31
IL228425A0 (en) 2013-12-31
JP2014508174A (ja) 2014-04-03
KR20140038383A (ko) 2014-03-28
SMT201800221T1 (it) 2018-07-17
NZ712273A (en) 2016-09-30
MX359947B (es) 2018-10-17
ZA201306933B (en) 2016-07-27
US9198955B2 (en) 2015-12-01
US20200046804A1 (en) 2020-02-13
EA028448B1 (ru) 2017-11-30
US10500254B2 (en) 2019-12-10
US20250276042A1 (en) 2025-09-04
JP2018030847A (ja) 2018-03-01

Similar Documents

Publication Publication Date Title
Zhang et al. Just how prevalent are peptide therapeutic products? A critical review
NZ599558A (en) Dosing regimen associated with long-acting injectable paliperidone esters
MY149419A (en) Dosing and drive mechanism for drug delivery device
MX2009005098A (es) Mecanismo dosificador y accionador para dispositivos de descarga de farmacos.
NZ599309A (en) Palm activated drug delivery device
JP2013509435A5 (cg-RX-API-DMAC7.html)
MY148971A (en) Improvements in and relating to drive mechanisms suitable for use in drug delivery devices
HRP20231151T1 (hr) Režimi za doziranje spojeva iz klase ehinokandina
HRP20210624T1 (hr) Režimi doziranja amisulprida za liječenje mučnine i povraćanja
CO6361944A2 (es) Combinacion de una insulina y un agonista de glp-1
SI2625199T1 (en) Procedures for treating psoriasis using IL-17 antagonists
IL159662A0 (en) Administration appliance comprising a dosage device
HRP20201027T1 (hr) Režim doziranja za propuštene doze injektibilnih estera paliperidona s produljenim djelovanjem
JP2018510898A5 (cg-RX-API-DMAC7.html)
SI2686002T1 (en) A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen
RU2008138381A (ru) Режимы дозирования адреналина
MX2022008236A (es) Metodos para administrar altas concentraciones de oxido nitrico.
WO2012052853A3 (en) Oral dosing device for administration of medication
JP2018510894A5 (cg-RX-API-DMAC7.html)
HRP20201388T1 (hr) Režimi i postupci liječenja multiple skleroze uporabom ofatumumaba
JP2019511506A5 (cg-RX-API-DMAC7.html)
MX2018000258A (es) Dispositivo de suministro de un solo uso.
MX2023010313A (es) Formulación y métodos de gliburida de baja sorción.
RU2013150024A (ru) Способы контроля и лечения хронической боли с применением hcg
JP2014508174A5 (cg-RX-API-DMAC7.html)